Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality

Ergönül, Önder; Aydın, Mehtap; Azap, Alpay; Başaran, Seniha; Tekin, Süda; Kaya, Şafak; Gülsün, Serda; Yörük, Gülşen; Kurşun, Ebru; Yeşilkaya, Ayşegül; Şimşek, Fatma; Yılmaz, Emel; Bilgin, Hüseyin; Hatipoğlu, Çiğdem Ataman; Çabadak, Hatice; Tezer, Yasemin; Togan, Turhan; Karaoğlan, İlkay; İnan, Asuman; Engin, Aynur; Alışkan, Hikmet Eda; Yavuz, Serap Şimşek; Erdinç, Şebnem; Mülazımoğlu, Lütfiye; Azap, Özlem Kurt; Can, Füsun; Akalın, Halis; Timurkaynak, Funda

doi:10.1016/j.jhin.2016.08.012

Cited by 48 publications

(28 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As of April 2016, 48 states in the USA had reported the presence of CRE arising from KPC, 25 reporting NDM, 19 reporting OXA-48 and 6 reporting VIM [20]. Colistin is one of the few treatment options available for CRE, yet increasing accounts of colistin resistance are also being documented [21,22]. The first report of plasmid-borne colistin resistance ( mcr-1 ) has been identified among multidrug-resistant E. coli in the USA, leading to concerns of pandrug-resistant bacteria [23].…”

Section: Epidemiology Of Carbapenem Resistancementioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in the community: a scoping review

Kelly

Mathema

Larson

2017

International Journal of Antimicrobial Agents

187

141

View full text Add to dashboard Cite

Carbapenem antibiotics are used as a last resort to treat serious Gram-negative bacteria (GNB) infections, however carbapenemase-producing strains of GNB have emerged as a major source of resistance. Owing to the highly transmissible nature of plasmid-borne carbapenemases, numerous reports have warned about the likely spread into the community from healthcare settings. Since the prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in the community is largely unknown, we conducted a scoping review of the literature to assess the percentage of CRE isolates that could be associated with the community. Initially, 361 studies were assessed and 15 met the inclusion criteria. Although 5 studies (33.3%) found no community-associated CRE, the remaining 10 studies identified percentages ranging from 0.04% to 29.5% of either community-associated or community-onset CRE among their samples, with US-based studies alone ranging from 5.6–10.8%. The presence of CRE in the community poses an urgent public health threat.

show abstract

Section: Epidemiology Of Carbapenem Resistancementioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in the community: a scoping review

Kelly

Mathema

Larson

2017

International Journal of Antimicrobial Agents

187

141

View full text Add to dashboard Cite

show abstract

“…Italy (36%) (Capone et al, 2013) and Greece (14%) (Mavroidi et al, 2016) have the highest rates of colistin resistance in K. pneumoniae. In Turkey, the prevalence of colistin resistance increased from 6% in 2013 to 16% in 2014-2015 among Kp-BSI (Ergonul et al, 2016). In this study, the rate of colistin resistance was 29% among Kp-BSI overall and 53% among the strains with carbapenem resistance.…”

Section: Discussionmentioning

confidence: 50%

The Excision of the Buccal Fat Pad for Cheek Refinement: Volumetric Considerations

Sezgin

Tatar

Böge

et al. 2018

Aesthetic Surgery Journal

View full text Add to dashboard Cite

show abstract

“…The incidence of severe infections caused by Gram negative bacteria continues to increase, particularly with advances in medical care, and remains a major contributor to morbidity and mortality with variation between countries and between hospitals [1,2]. The variable mortality rates of patients with severe infections caused by Gram negative bacteria depends largely on antibiotic resistance but also on differences involving the populations analyzed, including those related to age and underlying disease/comorbidity profiles [3].…”

mentioning

confidence: 99%